Showing 26–50 of 145 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Michelle A Kendall, Michael D Hughes, Soyeon Kim, Lisa A Aaron, Linda Naini, et al.
**INTRODUCTION:** Data to guide tuberculosis (TB) preventive treatment (TPT) of close contacts of people with multidrug-resistant tuberculosis (MDR-TB) are limited. While levofloxacin-based TPT has been shown safe and efficacious, alternatives are needed for those exposed to fluo…
Norbert Heinrich, Christina Manyama, Simon E Koele, Stellah Mpagama, Francis Mhimbira, et al.
…component globally in first-line therapy for drug-resistant tuberculosis but has considerable toxicity. New and safer alternative oxazolidinones are needed. Sutezolid is one such promising alternative. We aimed to evaluate preliminary efficacy and safety of sutezolid and to ident…
Degu Jerene, Kristian van Kalmthout, Jens Levy, Jason Alacapa, Natasha Deyanova, et al.
…CKGROUND:** The impact of digital adherence technologies on tuberculosis treatment outcomes remains poorly understood. We investigated whether smart pillboxes and medication labels can reduce poor treatment outcomes in patients with tuberculosis. **METHODS:** We did independent …
Feng Sun, Yang Li, Yilin Zhang, Cui Cai, Yuanyuan Chen, et al.
…e advancements in shorter, oral regimens for drug-resistant tuberculosis, more options are needed to extent patient benefits. We conducted a trial to evaluate the noninferiority of an all-oral regimen compared with the injectable-containing regimen. **METHODS:** In an open-label…
Haoxin Xu, Jingyu Zhou, Qingluan Yang, Yixuan Yang, Feiran Zhou, et al.
… the higher specificity and reliability of detecting latent tuberculosis (TB) infection, Mycobacterium tuberculosis-specific interferon (IFN)-γ release assays do not perform satisfactorily in predicting the risk of active TB (ATB) development. It is crucial to identify new …
Veronique de Jager, Laurynas Mockeliunas, Huifang You, Ulrika S H Simonsson, Tarryn Collings, et al.
…ctivity of rifampicin in rifampicin-resistant Mycobacterium tuberculosis strains. This phase 2a trial aimed to determine if addition of rifampicin increases the early bactericidal activity (EBA) of meropenem plus amoxicillin/clavulanate in patients with rifampicin-resistant tuber…
Bella Devaleenal Daniel, Sivakumar Shanmugam, Rashi Mehta, Manpreet Bhalla, Muthuvijayalakshmi Mariappan, et al.
… at the end of 48 weeks post treatment among drug resistant tuberculosis (DR TB) patients. **METHODS:** Multicentric pragmatic randomized clinical trial in which BPaL regimens were given for 26 weeks for pulmonary pre extensively drug resistant tuberculosis (PreXDR TB); bedaquil…
Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, Meredith G Dixon, Kelly E Dooley, et al.
…or efficacy of 4-month rifapentine/moxifloxacin regimen for tuberculosis (TB) treatment compared with the standard regimen. We analyzed pregnancy outcomes of women who became pregnant during the study. Among 740 women, 97 (13.1%) became pregnant. Of 102 pregnancies (in 97 pa…
Prakash Ghosh, Shaheda Anwar, Martin Siegel, Julius Boniface Okuni, Manfred Weidmann, et al.
**INTRODUCTION:** Early and accurate diagnosis of tuberculosis (TB) is central to ensuring the proper treatment and curbing the transmission of the disease. Despite the significant burden, the diagnosis of peripheral lymph node(LN)TB, the most prevalent form of extra pulmonary tu…
Pichanon Mingchay, Kamon Kawkitinarong, Pattama Torvorapanit, Pirapon June Ohata, Gompol Suwanpimolkul
**BACKGROUND:** Delayed pulmonary tuberculosis (PTB) diagnosis, especially with limited bronchoscopy resources, worsens outcomes and increases transmission risks. Sputum induction offers a noninvasive and effective alternative. We investigated whether adding nebulized bronchodila…
Saskia Janssen, Caryn Upton, Veronique R de Jager, Christo van Niekerk, Rodney Dawson, et al.
…ty, safety, and pharmacokinetics in patients with pulmonary tuberculosis and to summarize its current state of development for other diseases.We randomly assigned 64 patients with smear-positive, drug-sensitive tuberculosis to daily telacebec 100, 200, or 300 mg, or standard four…
Maria Del Mar Castro, Celso Khosa, Grace Mhalu, Lonze Ndelwa, Simeon Mwanyonga, et al.
…y and appropriate diagnosis and treatment are key to ending tuberculosis (TB). Incorporating users' preferences when implementing decentralised strategies for diagnosis may facilitate scale-up and impact. This qualitative study embedded within a cluster randomised controlled tria…
M Olugbosi, M Beumont, L Lombard, J Nedelman, J Timm, et al.
**INTRODUCTION:** In 2023, tuberculosis (TB) returned to being the world's leading cause of death from a single infectious agent. Current standard of care for drug-sensitive tuberculosis (DS-TB) treatment has a long duration with risk of poor compliance and outcomes and increased…
Nicholas I Paton, Christopher Cousins, Intan P Sari, Erlina Burhan, Nan-Kai Ng, et al.
…l duration for new drug regimens for rifampicin-susceptible tuberculosis. We aimed to investigate the efficacy and safety of the 8-week regimens that were assessed as part of the TRUNCATE management strategy of the TRUNCATE-TB trial. **METHODS:** TRUNCATE-TB was a multi-arm, mul…
Diego de Faria Magalhães Torres, Fernando Silva Guimarães, Nathanael Augusto Soares Meireles, Alexandre Pinto Cardoso, Giovanni Battista Migliori, et al.
…and treatment, approximately 50% of individuals affected by tuberculosis develop post-tuberculosis lung disease (PTLD), leading to functional limitations and reduced quality of life (QoL). Pulmonary rehabilitation programs have demonstrated benefits in patients with PTLD; however…
Weijie Kong, Hao Liang, Yi Zhang, Lei Li, Yongguo Li, et al.
…DQ) received conditional approval for multi-drug resistance tuberculosis (MDR-TB), a black box warning was added due to QT prolongation risk. WX-081, a promising second-in-class drug that finished phase II clinical trial, exhibited comparable anti-TB activity and better cardiac s…
Hamu J Mlyuka, Alphonce Liyoyo, Belinda Nyaulingo, Emmanuel Mpolya, Oscar L Kaswaga, et al.
…rrent combination antibiotic treatment for drug-susceptible tuberculosis (DS-TB) usually takes 6 months to complete. This long duration can compromise clinical outcomes. Although a 4-month regimen including an optimized dose of rifapentine plus moxifloxacin is non-inferior to sta…
Fajri Gafar, Elin M Svensson, Vycke Yunivita, Federica Fregonese, Dina Fisher, et al.
…ACKGROUND:** High-dose rifampicin could potentially shorten tuberculosis preventive therapy (TPT) and improve outcomes. We aimed to characterize population pharmacokinetics of standard- and high-dose rifampicin for TPT among individuals with tuberculosis infection. **METHODS:** …
Javier Roberti, Priscilla Carmiol-Rodríguez, Enrique Chan-Liang, Omar Alfonso Aguilar-Vidrio, Agnes A Suyanto, et al.
…pporting adherence to complex treatment regimens, including tuberculosis (TB) treatment. However, better understanding is needed of how users engage with DATs and how engagement influences their effectiveness, particularly in real-world settings and among underserved populations.…
Nicole Salazar-Austin, Silvia Cohn, Bareng A S Nonyane, Christiaan Mulder, Fiseha Mulatu, et al.
**BACKGROUND:** Tuberculosis preventive treatment (TPT) is highly effective at preventing tuberculosis (TB) disease but is poorly implemented. We aimed to determine whether home-based contact management improves TPT uptake among close child contacts compared to the facility-based…
Saskia Janssen, Thanakorn Vongjarudech, Mats O Karlsson, Caryn M Upton, Anthony J Garcia-Prats, et al.
…12-dose, once-weekly, rifapentine-based (3HP), short-course tuberculosis preventive treatment (TPT) in children has been limited due to a lack of child-friendly rifapentine formulations. In this study, we compared the relative bioavailability of rifapentine and isoniazid when sus…
Aline Mendes Leal Rodrigues de Souza, Davi Luiz Olimpio da Silva, Matheus Mello da Silva, Laura Lima da Silva, Ursula Damiana Pereira Vasques da Silva, et al.
**BACKGROUND AND PURPOSE:** Tuberculosis primarily affects the lungs, and many patients experience sequelae, including loss of lung function and a decline in health-related quality of life (HRQoL), despite bacteriological cure. Although post-tuberculosis lung disease (PTLD) is a …
Fayaz Ahmad, Maryiam Rahim, Fatima Khalid Qazi, Zohaib Khan, Shaista Rasool, et al.
**BACKGROUND:** Tuberculosis (TB) remains a significant public health challenge, particularly in low- and middle-income countries (LMICs) such as Pakistan, where TB and depression frequently co-occur, negatively impacting treatment adherence and outcomes. The cognitive therapy fo…
Yue-Ying Zhou, Hui-Juan Li, Kai-Jia Wu, Ji-Chan Shi, Xian-Gao Jiang, et al.
…mbined with medication in the treatment of tracheobronchial tuberculosis (TBTB). **METHODS:** This study was designed as a prospective, randomized clinical trial. 96 patients with newly diagnosed TBTB were collected and divided into the study group (n = 48) and the…
Weijian Liu, Nuo Xu, Wei Li, Wen Yao Mak, Tian He, et al.
…ety of 4-week daily rifapentine-isoniazid regimen in latent tuberculosis for Chinese children, and to provide paediatric-specific evidence for extrapolating adult dosing strategies to children. **METHODS:** An open-label, prospective, single-arm clinical trial was conducted amon…